Windtree Therapeutics (NASDAQ: WINT – Get Rating) and Innate Pharma (NASDAQ: IPHA – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.
Analyst Recommendations:
This is a breakdown of recent ratings and recommmendations for Windtree Therapeutics and Innate Pharma, as provided by MarketBeat.com.
| Sell Ratings: | Hold Ratings: | Buy Ratings: | Strong Buy Ratings: | Rating Score: | |
| Windtree Therapeutics: | 0: | 0: | 0: | 0: | N / A: |
| Innate Pharma: | 0: | 0: | 4: | 0: | 3.00: |
Innate Pharma has a consensus target price of $ 11.13, indicating a potential upside of 284.95%. Given Innate Pharma’s higher possible upside, analysts clearly believe Innate Pharma is more favorable than Windtree Therapeutics.
Insider & Institutional Ownership:
11.4% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 1.7% of Innate Pharma shares are owned by institutional investors. 16.7% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability:
This table compares Windtree Therapeutics and Innate Pharma’s net margins, return on equity and return on assets.
| Net Margins: | Return on Equity: | Return on Assets: | |
| Windtree Therapeutics: | N / A: | -145.63% | -84.17% |
| Innate Pharma: | N / A: | N / A: | N / A: |
Risk and Volatility:
Windtree Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.
Earnings & Valuation:
This table compares Windtree Therapeutics and Innate Pharma’s revenue, earnings per share and valuation.
| Gross Revenue: | Price / Sales Ratio: | Net Income: | Earnings Per Share: | Price / Earnings Ratio: | |
| Windtree Therapeutics: | $ 200,000.00: | 61.75: | – $ 67.64 million: | ($ 2.48) | -0.17: |
| Innate Pharma: | $ 29.23 million: | 7.88: | – $ 62.48 million: | N / A: | N / A: |
Innate Pharma has higher revenue and earnings than Windtree Therapeutics.
Summary:
Innate Pharma beats Windtree Therapeutics on 6 of the 9 factors compared between the two stocks.
About Windtree Therapeutics: (Get Rating)
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company’s lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, SA for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for the development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee’s Pharmaceutical Holdings Limited.
About Innate Pharma: (Get Rating)
Innate Pharma SA, a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory cesarean section syndrome. ; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinical trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA / B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma SA has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A / S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Receive News & Ratings for Windtree Therapeutics Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Windtree Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
.